Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
复制标题
来那度胺和利妥昔单抗的新型组合随后进行干细胞移植治疗复发/难治性侵袭性 B 细胞非霍奇金淋巴瘤的临床结果
DOI：
10.18632/oncotarget.2255
复制
发表时间：
2014-09-15
期刊：
影响因子：
--
通讯作者：
Wang M
中科院分区：
文献类型：
--
作者：
Cai Q;Chen Y;Zou D;Zhang L;Badillo M;Zhou S;Lopez E;Jiang W;Huang H;Lin T;Romaguera J;Wang M
我们回顾性比较了复发性/难治性非霍奇金淋巴瘤（NHL）患者的结局，这些患者接受了干细胞移植（SCT），在来那度胺和利妥昔单抗（LR）的新型联合治疗后病情稳定或更好，并且在I/II期临床试验中没有接受SCT。我们回顾性比较了接受SCT的患者与LR治疗后病情稳定或好转但未接受SCT的患者的结局。入选LR临床试验并接受SCT的22例患者中，13例为套细胞淋巴瘤（MCL），9例为大B细胞淋巴瘤（LBCL）。所有接受螺旋CT的患者均获得完全缓解。在MCL亚群中，除了非SCT患者年龄较大且具有较高的套细胞国际预后指数评分外，SCT组和非SCT组之间无显著差异。SCT组和非SCT组在缓解时间（P=0.3）、无进展生存期（PFS）（P=0.304）和总生存期（OS）（P=0.87）方面无差异。在LBCL亚组中，除非SCT组的国际预后指数评分较高外，两组间无显著性差异。接受SCT的LBCL患者的缓解持续时间（P=0.001）、PFS（P=0.000）和OS（P=0.003）显著长于非SCT组。新的治疗组合为复发性/难治性侵袭性B细胞NHL患者提供了SCT的桥梁。
We retrospectively compared outcomes of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with stable disease or better following a novel combination of lenalidomide and rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical trial. We retrospectively compared outcomes of patients who underwent SCT with that of patients who had stable disease or better following LR treatment and did not undergo SCT. Twenty-two patients enrolled in LR clinical trial and undergone SCT were identified, 13 with mantle cell lymphoma (MCL) and nine with large B-cell lymphoma (LBCL). All patients who underwent SCT achieved complete response. In the MCL subset, there were no significant differences between SCT and non-SCT groups except that non-SCT patients were older and had a higher mantle-cell international prognostic index score. There was no difference between SCT-group and non-SCT-group in response duration (P=0.3), progression-free survival (PFS) (P=0.304) and overall survival (OS) (P=0.87). In LBCL subgroup, there were no significant differences between two groups except that non-SCT group had a higher international prognostic index score. Patients with LBCL who underwent SCT had significantly longer response duration (P=0.001), PFS (P=0.000), and OS (P=0.003) than the non-SCT group. The novel therapeutic combination offers a bridge to SCT in patients with relapsed/refractory aggressive B-cell NHL.
登录
查看更多内容
影响因子：
6.2
作者：
Bishop MR;Dean RM;Steinberg SM;Odom J;Pollack SM;Pavletic SZ;Sportes C;Gress RE;Fowler DH
通讯作者：
Fowler DH
影响因子：
45.3
作者：
Badoux, Xavier C.;Keating, Michael J.;Ferrajoli, Alessandra
通讯作者：
Ferrajoli, Alessandra
DOI：
10.1016/j.bbmt.2009.01.010
发表时间：
2009-05
期刊：
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
影响因子：
--
作者：
Hamadani M;Benson DM Jr;Hofmeister CC;Elder P;Blum W;Porcu P;Garzon R;Blum KA;Lin TS;Marcucci G;Devine SM
通讯作者：
Devine SM
影响因子：
20.3
作者：
Maris, MB;Sandmaier, BM;Maloney, DG
通讯作者：
Maloney, DG
影响因子：
51.1
作者：
Pfreundschuh, Michael;Schubert, Joerg;Loeffler, Markus
通讯作者：
Loeffler, Markus